Cycle Pharmaceuticals has announced the launch of dasatinib tablets (PHYRAGO) in partnership with Handa Therapeutics, LLC. The dasatinib will be exclusively available through the specialty pharmacy Onco360.
Dasatinib is a tyrosine kinase inhibitor bioequivalent to Sprycel, and treats adults with newly diagnosed or resistant/intolerant Philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia. It also treats pediatric patients 1 year and older with Ph+ CML in chronic phase or newly diagnosed Ph+ ALL in combination with chemotherapy.
PHYRAGO, Cycle Pharmaceuticals’ first oncology product in the US, allows concomitant use of proton pump inhibitors and H2 receptor antagonists to manage gastric acid disorders according to the press release.
The product will be distributed from McKesson, Cencora, and Cardinal Health.
Cycle Vita, a patient support program for those taking dasatinib, offers eligible patients medication access, financial savings like co-pay assistance, and clinical guidance with a dedicated team to ease treatment navigation, according to the press release.
“We understand the daily challenges that come with managing Ph+ CML and Ph+ ALL, and our goal is to ease that burden, not just with an improved formulation of dasatinib, but through the individualized care and hands-on support offered by our Cycle Vita program.” said Steve Fuller, chief strategy officer at Cycle Pharmaceuticals.
